Welcome to your daily briefing on healthcare developments in Massachusetts. Today we're covering 5 key stories including updates on massachusetts healthcare headlines, background & context. Let's dive in.
2 stories
This page provides links to key data resources used by the Research and Evaluation staff.
For healthcare professionals in MA, this centralized list can help support data-driven planning, evaluation, and reporting.
Physicians Thrive provides a Massachusetts-focused 2024 guide on how to use the Medical License Lookup to verify physician credentials and points to additional eLicense resources.
For MA healthcare professionals, quick and direct licensure checks help support safe clinical staffing, referrals, and professional credentialing by confirming who is currently authorized to practice.
Reach healthcare professionals
3 stories
A vendor is a business associate if they create, receive, maintain, or transmit PHI on behalf of the covered entity. They are NOT a business associate just because they happen to be in a building with PHI or could conceivably access it. The functional test matters, not the proximity test.
Forcing BAA execution on vendors who do not meet the functional test creates contractual bloat and weakens the negotiating position with vendors who actually do. Failing to execute BAAs with true business associates exposes the covered entity to OCR enforcement.
Across most payors, the top-five denial reasons account for over 80% of prior-auth rejections: missing clinical documentation, wrong CPT/HCPCS code, service not in benefit plan, step-therapy not completed, and ordering provider not on the patient's plan. The same five repeat across plans because they are the easiest to deny on automation.
Practices that build a five-line pre-submission checklist around these reasons typically cut prior-auth denials by 40-60% within a quarter. The fix is process, not appeals capacity.
Covered entities must annually recertify their 340B eligibility through HRSA. Missing the recertification window pushes the entity to inactive status, which means immediate loss of 340B pricing and potentially diversion violations on previously dispensed drugs. Reinstatement requires a new application.
The discount value of 340B pricing for a covered entity often exceeds six figures annually. Letting the recertification lapse for paperwork reasons is one of the most expensive administrative errors in the regulation.
Get Massachusetts healthcare intelligence delivered to your inbox every morning.
Subscribe FreeView all past issues
Feature your brand across the U.S., Canada, and select international markets and 10 industry verticals.
Become a National Partner